COAG
HealthcareHemab Therapeutics Holdings, Inc. Common Stock
Key Drivers
- Strong Liquidity
- Ongoing Cash Burn
- Equity Dependence
AIAI Summary
COAG is a well-funded but pre-revenue clinical-stage option whose upside hinges on sutacimig successfully entering and validating Phase 3, while early pipeline programs and likely future dilution keep the shares high risk until bleeding-reduction efficacy is proven.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Ongoing Cash Burn
- •Equity Dependence
COAG has exceptional liquidity and minimal debt, but persistent losses, negative cash flow, no revenue, and reliance on equity issuance make the shares appear high-risk at 5.32x book value.
Price Behavior
Key Price Behavior Insights:
- •Persistent downtrend
- •Support stabilization
- •Resistance reclaim
COAG remains bearish over the last month, with support at $39.40–$40.10 and downside risk prevailing unless it reclaims $44.40–$44.70 after its sharp September drop.
Sharp drop in early
Sentiment & News
Key News Insights:
- •Phase 1 start
- •First patient dosed
- •No clinical data
Hemab dosed the first Phase 1 participant for HMB-003 in heavy menstrual bleeding, a positive early clinical milestone but with no efficacy or safety data yet.
The trial initiation is a modestly positive catalyst for COAG, though meaningful valuation impact will depend on future safety and efficacy results
Similar Companies in Healthcare
Other companies in the same sector with AI ratings